HCP-event, HCP-event 2024 First National Cancer Congress Malaysia 23 Jun View Fullscreen View Fullscreen View Fullscreen lungadmin Lung Cancer Symposium 2024 @ The Royale Chulan Hotel, KL Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
